Research shows that GLP-1 receptor agonists and SGLT2 inhibitors are the most effective medications for treating metabolic dysfunction-associated steatotic liver disease (MASH), especially in people with type 2 diabetes. According to Gram Research analysis of this 2026 review in Diabetologia, these drugs not only improve liver health but also protect the heart and kidneys. Combined with diet and exercise, these medications represent a major advance in treating the world’s most common cause of chronic liver disease.
A major review published in Diabetologia examines how medications can treat metabolic dysfunction-associated steatotic liver disease (MASH), a condition where fat builds up in the liver. According to Gram Research analysis, two types of drugs—GLP-1 receptor agonists and SGLT2 inhibitors—show the most promise, especially for people with type 2 diabetes. These medications not only help the liver but also protect the heart and kidneys. The review emphasizes that while lifestyle changes like diet and exercise remain essential, these new pharmacological treatments offer hope for millions worldwide suffering from this increasingly common liver condition.
Key Statistics
A 2026 narrative review in Diabetologia found that GLP-1 receptor agonists and SGLT2 inhibitors are the preferred pharmacological treatments for MASH in people with type 2 diabetes, offering benefits to the liver, heart, and kidneys simultaneously.
According to research reviewed by Gram, metabolic dysfunction-associated steatotic liver disease (MASH) is now the leading cause of chronic liver disease worldwide, with strong associations to type 2 diabetes, cardiovascular disease, and chronic kidney disease.
A 2026 Diabetologia review identified that MASH shares common causes with type 2 diabetes, driven primarily by unhealthy diet, insulin resistance, and low-grade inflammation, making dual-action medications particularly effective.
The Quick Take
- What they studied: Which medications work best to treat fatty liver disease, particularly in people with type 2 diabetes
- Who participated: This was a review article that analyzed existing research on drug treatments for MASH rather than conducting a new study with participants
- Key finding: Two drug classes—GLP-1 receptor agonists and SGLT2 inhibitors—are most effective for treating fatty liver disease and also protect heart and kidney health
- What it means for you: If you have fatty liver disease and type 2 diabetes, ask your doctor about these medications as they may help your liver while also reducing your risk of heart and kidney problems
The Research Details
This is a narrative review, meaning experts examined and summarized all the available research on drug treatments for MASH. Rather than conducting their own experiment with patients, the researchers looked at what other scientists have discovered about how different medications affect fatty liver disease. They focused especially on two types of drugs: GLP-1 receptor agonists (which help control blood sugar and weight) and SGLT2 inhibitors (which help the kidneys remove excess sugar through urine). The review also discussed other treatment approaches and how they work in the body.
A review like this is valuable because it brings together all the scattered research findings into one place, helping doctors and patients understand which treatments have the strongest evidence behind them. Since MASH is becoming the most common cause of liver disease worldwide, having clear guidance on medication options is critically important. The review also highlights how these liver treatments benefit other organs like the heart and kidneys, which matters because people with fatty liver disease often have multiple health problems.
This review was published in Diabetologia, a respected medical journal focused on diabetes and metabolic diseases. As a narrative review, it provides expert interpretation rather than statistical analysis of combined data. The strength of this review depends on the quality of the individual studies it examined. Readers should note that while the authors are experts in the field, a narrative review is generally considered less definitive than a systematic review or meta-analysis that uses strict statistical methods.
What the Results Show
The review found that GLP-1 receptor agonists are among the most effective medications for treating MASH, particularly in people with type 2 diabetes. These drugs work by helping the body control blood sugar, reduce weight, and decrease inflammation in the liver. The research shows they improve liver health while also protecting the heart and kidneys—a major advantage since people with fatty liver disease often have heart and kidney problems too. SGLT2 inhibitors, another class of diabetes medication, showed similar benefits. These drugs help the kidneys remove excess sugar, which reduces the workload on the liver and improves overall metabolic health. The review emphasizes that both drug classes provide what doctors call ‘cardiorenal benefits,’ meaning they protect multiple organs beyond just the liver.
The review also discussed other treatment approaches for MASH beyond GLP-1 and SGLT2 inhibitors, though these showed less consistent benefits. The authors stressed that lifestyle interventions—eating a healthy low-calorie diet and increasing physical activity—remain the foundation of treatment and should be combined with medication. The review highlighted that MASH exists on a spectrum, ranging from simple fat accumulation to more serious conditions like cirrhosis, and that different patients may respond differently to the same medications. This variation in how people respond suggests that personalized treatment approaches may be necessary in the future.
This review builds on growing evidence that GLP-1 and SGLT2 medications benefit the liver. Previous research had shown these drugs help with diabetes and weight loss, but newer studies demonstrate they specifically improve liver health in people with MASH. The review represents a shift in how doctors think about treating fatty liver disease—moving away from the idea that only lifestyle changes work, toward recognizing that medications can be valuable partners in treatment. The emphasis on these drugs’ benefits for the heart and kidneys reflects an important realization: treating MASH isn’t just about the liver, but about protecting overall health in people with multiple metabolic problems.
As a narrative review rather than a systematic analysis, this article reflects the authors’ expert judgment about which studies are most important, which could introduce some bias. The review doesn’t provide a statistical summary of how many studies support each conclusion or how large the treatment effects are across all research. Individual studies examining these medications may have different quality levels and patient populations, making it difficult to know exactly how well results apply to all patients. The review also focuses mainly on people with type 2 diabetes, so findings may not apply equally to people with MASH who don’t have diabetes.
The Bottom Line
If you have MASH and type 2 diabetes, discuss GLP-1 receptor agonists or SGLT2 inhibitors with your doctor as first-line medication options (high confidence). Continue or start a healthy diet and regular exercise, as these remain essential (high confidence). If you have MASH without diabetes, ask your doctor about emerging treatment options, as the evidence is strongest for people with both conditions (moderate confidence). Do not stop or change medications without medical guidance.
This research is most relevant for people with MASH and type 2 diabetes, who represent a large portion of MASH patients. It’s also important for people with MASH who don’t have diabetes but are at risk for heart or kidney disease. Healthcare providers treating liver disease, diabetes, or cardiometabolic conditions should be aware of these medication options. People with simple fatty liver (without inflammation) should discuss with their doctor whether these medications apply to their situation.
Improvements in liver health from GLP-1 or SGLT2 inhibitors typically take several months to become apparent, with more significant changes visible after 6-12 months of consistent treatment. Weight loss and blood sugar improvements may appear sooner (4-8 weeks). Long-term benefits for preventing liver cirrhosis and protecting heart and kidney function develop over years of treatment. Results vary by individual based on starting severity, medication adherence, and lifestyle changes.
Frequently Asked Questions
What medications treat fatty liver disease?
GLP-1 receptor agonists and SGLT2 inhibitors are the most effective medications for MASH, particularly for people with type 2 diabetes. These drugs improve liver health while also protecting the heart and kidneys. Always consult your doctor about which medication suits your specific situation.
Can medication alone cure fatty liver disease?
Medications work best when combined with lifestyle changes like healthy eating and exercise. While GLP-1 and SGLT2 inhibitors significantly improve MASH, diet and physical activity remain the foundation of treatment. Your doctor can determine the right combination for you.
How long does it take for liver medication to work?
Improvements in liver health typically appear after 3-6 months of consistent treatment, with more significant changes visible after 6-12 months. Weight loss and blood sugar improvements may occur sooner. Results vary by individual and depend on medication adherence and lifestyle changes.
Do I need these medications if I don’t have diabetes?
The strongest evidence for GLP-1 and SGLT2 inhibitors applies to people with both MASH and type 2 diabetes. If you have MASH without diabetes, discuss with your doctor whether these medications are appropriate for your specific health situation and risk factors.
What causes metabolic dysfunction-associated steatotic liver disease?
MASH develops from unhealthy diet, excess weight, insulin resistance, and chronic inflammation. These factors cause fat to accumulate in the liver and trigger inflammation. The condition is strongly linked to type 2 diabetes, heart disease, and kidney disease, which share similar underlying causes.
Want to Apply This Research?
- Track liver enzyme levels (ALT and AST) every 3 months if your doctor orders blood tests, recording the specific numbers to monitor improvement over time
- Set daily reminders for medication adherence combined with logging meals to ensure you’re following both the medication regimen and dietary recommendations your doctor prescribed
- Create a monthly check-in routine documenting energy levels, weight trends, and any digestive changes, then review patterns quarterly with your healthcare provider to assess treatment effectiveness
This article summarizes research on MASH treatment and should not replace professional medical advice. Medications mentioned carry specific risks, benefits, and contraindications that vary by individual. Do not start, stop, or change any medication without consulting your healthcare provider. If you have fatty liver disease, work with your doctor to develop a personalized treatment plan combining medication, diet, and exercise. This review reflects current research but treatment recommendations may evolve as new evidence emerges.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.